Atlas Trials

the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment

Clinical trial NCT03358004 · TERMINATED

Trial details

NCT number
NCT03358004
Sponsor
Mario Negri Institute for Pharmacological Research
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2017-06-14
Primary completion
2018-09-13
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.